Analysis and therapeutic research for growth impairment accompanied with chronic inflammatory syndrome of children as dysregulation of proinflammatory cytokines

伴随系统性幼年特发性关节炎(SJIA)的生长发育障碍被认为与IL-6抑制软骨细胞的增殖有关，IL-6是引起全身炎症的关键细胞因子，皮质类固醇抑制骨延伸。Tocilizumab是一种抗IL-6受体抗体，于2008年在日本获得批准，因此现在被广泛用于治疗类固醇难治性或依赖性sJIA。本文调查了45例服用曲克西平的sJIA患者的身高和身高速度，分析了身高、身高速度与年龄、性别、病程、激素暴露等因素的相关性，身高标准差分数(HTSDS)与病程呈负相关，皮质激素减少与身高速度改善呈强相关。

Growth impairment accompanied with systemic juvenile idiopathic arthritis (sJIA) is thought to be associated with suppression of proliferation of chondrocyte by IL-6, the key cytokine causing systemic inflammation, and suppression of bone extension by corticosteroid. Tocilizumab, anti-IL-6 receptor antibody, was approved in 2008 in Japan, so now bloadly used as treatment for steroid-refractory or -dependent sJIA. We have investigated height and height velocity of 45 sJIA patient administered with TCZ and analyzed correlation between them and several factors such as age, gender, disease duration and corticosteroid exposure, then inverse correlation between standard deviation score for height (HTSDS) and disease duration and strong correlation between reduction of corticosteroid and improvement of height velocity.